AVTX Stock Analysis: Buy, Sell, or Hold?
AVTX - Avalo Therapeutics, Inc. Common Stock
$13.74
-0.22 (-1.58%)
▼
5d:
-12.98%
30d:
-0.29%
90d:
-25.16%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Get Alerted When AVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AVTX is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AVTX is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AVTX is currently trading at $13.74, which is considered oversold relative to its 30-day fair value range of $13.87 to $19.43.
Technical Outlook: Technically, AVTX is showing sideways momentum. The price is currently testing key support at $13.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $46.18 (+236.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AVTX is showing sideways momentum. The price is currently testing key support at $13.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $46.18 (+236.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.87 -
$19.43
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 236.1% below Wall St target ($46.18)
- WARNING: Recommendation downgraded due to -13.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$13.87 -
$19.43
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.76
Resistance Level
$17.10
Current Trend
Sideways
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.79
Wall Street Target
$46.18
(+236.1%)
Revenue Growth (YoY)
-69.3%
Share & Embed Analysis
Last updated: June 03, 2026 5:09 PM ET
Data refreshes hourly during market hours. Next update: 6:09 PM
Data refreshes hourly during market hours. Next update: 6:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Mittie Doyle
SELL
3970 shares
2026-04-06
Christopher Ryan Sullivan
SELL
7980 shares
2026-04-02
Christopher Ryan Sullivan
SELL
7979 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
